Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophagectomy | 8 | 2023 | 482 | 1.040 |
Why?
|
Lung Neoplasms | 25 | 2024 | 13589 | 0.840 |
Why?
|
Pneumonectomy | 11 | 2024 | 1159 | 0.770 |
Why?
|
Esophageal Neoplasms | 8 | 2023 | 1676 | 0.740 |
Why?
|
Pleural Neoplasms | 5 | 2024 | 612 | 0.720 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 12 | 2024 | 5426 | 0.640 |
Why?
|
Mesothelioma | 5 | 2024 | 811 | 0.550 |
Why?
|
Penetrance | 2 | 2014 | 384 | 0.460 |
Why?
|
Burnout, Professional | 1 | 2022 | 712 | 0.430 |
Why?
|
Genes, BRCA2 | 2 | 2014 | 592 | 0.420 |
Why?
|
Genes, BRCA1 | 2 | 2014 | 755 | 0.400 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2024 | 716 | 0.400 |
Why?
|
Breast | 2 | 2017 | 1976 | 0.370 |
Why?
|
Music Therapy | 2 | 2023 | 111 | 0.370 |
Why?
|
Neoplasms, Second Primary | 2 | 2014 | 1062 | 0.330 |
Why?
|
Neoadjuvant Therapy | 6 | 2023 | 2896 | 0.330 |
Why?
|
Heterozygote | 2 | 2014 | 2792 | 0.330 |
Why?
|
Palliative Care | 5 | 2024 | 3644 | 0.330 |
Why?
|
Bereavement | 2 | 2024 | 310 | 0.320 |
Why?
|
Neoplasms | 10 | 2024 | 22386 | 0.320 |
Why?
|
Sarcoma | 3 | 2024 | 1806 | 0.300 |
Why?
|
Models, Genetic | 2 | 2014 | 3442 | 0.280 |
Why?
|
Breast Neoplasms | 6 | 2017 | 21156 | 0.270 |
Why?
|
Thoracic Surgery | 2 | 2023 | 727 | 0.260 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 934 | 0.250 |
Why?
|
Neoplasm Staging | 15 | 2024 | 11249 | 0.240 |
Why?
|
Vincristine | 2 | 2024 | 1039 | 0.220 |
Why?
|
Bronchial Fistula | 1 | 2023 | 83 | 0.210 |
Why?
|
Ketones | 1 | 2024 | 182 | 0.210 |
Why?
|
Furans | 1 | 2024 | 201 | 0.210 |
Why?
|
Vaginal Diseases | 1 | 2023 | 103 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 11843 | 0.200 |
Why?
|
Pleural Diseases | 1 | 2023 | 138 | 0.200 |
Why?
|
Retrospective Studies | 30 | 2024 | 81834 | 0.200 |
Why?
|
Carbolines | 1 | 2024 | 296 | 0.200 |
Why?
|
Paclitaxel | 3 | 2024 | 1737 | 0.200 |
Why?
|
Empyema | 1 | 2021 | 41 | 0.190 |
Why?
|
CA-125 Antigen | 1 | 2024 | 281 | 0.190 |
Why?
|
Hemangiosarcoma | 1 | 2024 | 216 | 0.190 |
Why?
|
Granuloma, Foreign-Body | 1 | 2021 | 42 | 0.190 |
Why?
|
Liposarcoma | 1 | 2024 | 289 | 0.190 |
Why?
|
Interneurons | 2 | 2016 | 592 | 0.190 |
Why?
|
Thymoma | 1 | 2022 | 191 | 0.180 |
Why?
|
Carcinoma, Large Cell | 1 | 2021 | 114 | 0.180 |
Why?
|
Lymphatic Metastasis | 4 | 2021 | 2930 | 0.180 |
Why?
|
Precancerous Conditions | 3 | 2017 | 988 | 0.180 |
Why?
|
Humans | 75 | 2024 | 768451 | 0.180 |
Why?
|
Adenocarcinoma | 3 | 2023 | 6400 | 0.170 |
Why?
|
Keratins | 1 | 2021 | 502 | 0.170 |
Why?
|
Thoracic Neoplasms | 1 | 2022 | 270 | 0.170 |
Why?
|
Thymus Neoplasms | 1 | 2022 | 278 | 0.170 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2023 | 363 | 0.170 |
Why?
|
Leiomyosarcoma | 1 | 2024 | 425 | 0.170 |
Why?
|
Parents | 5 | 2024 | 3596 | 0.170 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2024 | 295 | 0.160 |
Why?
|
Doxorubicin | 2 | 2024 | 2229 | 0.160 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2024 | 451 | 0.160 |
Why?
|
Gastrostomy | 1 | 2022 | 325 | 0.160 |
Why?
|
Thoracic Surgical Procedures | 1 | 2023 | 350 | 0.160 |
Why?
|
Morals | 1 | 2022 | 289 | 0.160 |
Why?
|
Pneumothorax | 1 | 2022 | 393 | 0.160 |
Why?
|
Hyperplasia | 3 | 2017 | 1154 | 0.160 |
Why?
|
Aged | 29 | 2024 | 171520 | 0.160 |
Why?
|
Chlamydia trachomatis | 1 | 2019 | 239 | 0.140 |
Why?
|
Ependymoma | 1 | 2020 | 324 | 0.140 |
Why?
|
Hospices | 1 | 2020 | 245 | 0.140 |
Why?
|
raf Kinases | 1 | 2017 | 118 | 0.140 |
Why?
|
Learning Curve | 1 | 2018 | 233 | 0.140 |
Why?
|
Gastrectomy | 1 | 2021 | 696 | 0.130 |
Why?
|
Contact Tracing | 1 | 2019 | 275 | 0.130 |
Why?
|
Organ Culture Techniques | 2 | 2015 | 796 | 0.130 |
Why?
|
Female | 37 | 2024 | 396943 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9425 | 0.130 |
Why?
|
Surgical Procedures, Operative | 2 | 2024 | 1937 | 0.130 |
Why?
|
Hydrocarbons | 1 | 2016 | 105 | 0.130 |
Why?
|
Treatment Outcome | 17 | 2024 | 65409 | 0.130 |
Why?
|
Preoptic Area | 1 | 2016 | 132 | 0.130 |
Why?
|
Astrocytoma | 2 | 2017 | 780 | 0.130 |
Why?
|
Chlamydia Infections | 1 | 2019 | 365 | 0.120 |
Why?
|
Length of Stay | 3 | 2024 | 6521 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 752 | 0.120 |
Why?
|
Telencephalon | 1 | 2015 | 142 | 0.120 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2021 | 617 | 0.120 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1143 | 0.120 |
Why?
|
Survival Rate | 7 | 2023 | 12875 | 0.120 |
Why?
|
Drug Hypersensitivity | 1 | 2023 | 922 | 0.110 |
Why?
|
Carcinoma, Lobular | 2 | 2015 | 480 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6537 | 0.110 |
Why?
|
Middle Aged | 22 | 2024 | 223418 | 0.110 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 562 | 0.110 |
Why?
|
Hospice Care | 1 | 2020 | 679 | 0.110 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2021 | 959 | 0.110 |
Why?
|
Critical Illness | 2 | 2024 | 2754 | 0.100 |
Why?
|
Transcription Factors | 2 | 2024 | 12174 | 0.100 |
Why?
|
Adult | 21 | 2024 | 223542 | 0.100 |
Why?
|
Postoperative Complications | 7 | 2024 | 15880 | 0.100 |
Why?
|
Frail Elderly | 3 | 2023 | 774 | 0.100 |
Why?
|
Male | 29 | 2024 | 364781 | 0.100 |
Why?
|
Stress, Psychological | 3 | 2023 | 4538 | 0.100 |
Why?
|
Decision Support Systems, Clinical | 1 | 2021 | 1176 | 0.100 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2039 | 0.100 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2024 | 2823 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 952 | 0.100 |
Why?
|
Protein Multimerization | 1 | 2017 | 980 | 0.100 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 928 | 0.100 |
Why?
|
Prognosis | 8 | 2021 | 30028 | 0.100 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59680 | 0.100 |
Why?
|
Coculture Techniques | 1 | 2015 | 1343 | 0.100 |
Why?
|
Calibration | 1 | 2014 | 823 | 0.100 |
Why?
|
Neural Inhibition | 1 | 2015 | 588 | 0.090 |
Why?
|
Child | 13 | 2024 | 80863 | 0.090 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2430 | 0.090 |
Why?
|
Mammary Glands, Human | 1 | 2012 | 202 | 0.090 |
Why?
|
Anticarcinogenic Agents | 1 | 2012 | 251 | 0.090 |
Why?
|
Decision Support Techniques | 1 | 2021 | 2010 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2079 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8635 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2015 | 1092 | 0.090 |
Why?
|
Young Adult | 11 | 2024 | 60045 | 0.090 |
Why?
|
Chemoprevention | 1 | 2012 | 326 | 0.090 |
Why?
|
Geriatric Assessment | 3 | 2023 | 1422 | 0.090 |
Why?
|
Analgesics, Opioid | 3 | 2024 | 3837 | 0.090 |
Why?
|
Heart Diseases | 1 | 2023 | 2816 | 0.090 |
Why?
|
Carcinoma in Situ | 1 | 2015 | 791 | 0.080 |
Why?
|
Opioid-Related Disorders | 1 | 2024 | 2188 | 0.080 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 548 | 0.080 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3939 | 0.080 |
Why?
|
Decision Making | 1 | 2023 | 3961 | 0.080 |
Why?
|
Adolescent | 11 | 2024 | 89168 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2015 | 3623 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2017 | 1614 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2531 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13708 | 0.080 |
Why?
|
Lung | 3 | 2022 | 10090 | 0.080 |
Why?
|
Age Factors | 3 | 2024 | 18478 | 0.080 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 1076 | 0.070 |
Why?
|
HIV Antibodies | 1 | 2015 | 1341 | 0.070 |
Why?
|
Neural Stem Cells | 1 | 2015 | 892 | 0.070 |
Why?
|
SEER Program | 1 | 2012 | 1476 | 0.070 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 1625 | 0.070 |
Why?
|
Feasibility Studies | 3 | 2024 | 5308 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2017 | 2072 | 0.070 |
Why?
|
Quality of Life | 3 | 2024 | 13497 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26351 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4906 | 0.070 |
Why?
|
Pedigree | 1 | 2014 | 4545 | 0.070 |
Why?
|
Fibroblasts | 1 | 2016 | 4180 | 0.060 |
Why?
|
Mass Screening | 2 | 2019 | 5455 | 0.060 |
Why?
|
Risk Assessment | 4 | 2024 | 24311 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4083 | 0.060 |
Why?
|
Antibodies, Neutralizing | 1 | 2015 | 2008 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2017 | 9182 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1427 | 0.060 |
Why?
|
Bayes Theorem | 1 | 2012 | 2358 | 0.060 |
Why?
|
Peptides | 1 | 2016 | 4368 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2017 | 18048 | 0.060 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2024 | 221 | 0.050 |
Why?
|
Ifosfamide | 1 | 2023 | 234 | 0.050 |
Why?
|
Cell Movement | 1 | 2015 | 5223 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2742 | 0.050 |
Why?
|
Child Care | 1 | 2024 | 126 | 0.050 |
Why?
|
Nerve Net | 1 | 2015 | 2362 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4841 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2021 | 3550 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2015 | 3063 | 0.050 |
Why?
|
Risk Factors | 8 | 2024 | 74915 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 473 | 0.050 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 3230 | 0.050 |
Why?
|
Prospective Studies | 6 | 2024 | 54914 | 0.050 |
Why?
|
Nomograms | 1 | 2024 | 236 | 0.050 |
Why?
|
Thymectomy | 1 | 2022 | 200 | 0.050 |
Why?
|
Time Factors | 5 | 2024 | 40271 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2024 | 890 | 0.050 |
Why?
|
Infant | 4 | 2024 | 36497 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6135 | 0.050 |
Why?
|
Hypesthesia | 1 | 2021 | 106 | 0.050 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6856 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5709 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2024 | 624 | 0.040 |
Why?
|
Risk | 1 | 2012 | 9642 | 0.040 |
Why?
|
Grief | 1 | 2023 | 255 | 0.040 |
Why?
|
NAD | 1 | 2024 | 618 | 0.040 |
Why?
|
Boston | 2 | 2024 | 9361 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39430 | 0.040 |
Why?
|
Attitude to Death | 1 | 2023 | 401 | 0.040 |
Why?
|
Nerve Degeneration | 1 | 2024 | 750 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8730 | 0.040 |
Why?
|
Taxoids | 1 | 2023 | 669 | 0.040 |
Why?
|
Epinephrine | 1 | 2023 | 795 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2021 | 3472 | 0.040 |
Why?
|
Self Efficacy | 1 | 2024 | 651 | 0.040 |
Why?
|
Goals | 1 | 2024 | 715 | 0.040 |
Why?
|
Patient Care Planning | 1 | 2024 | 904 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10845 | 0.040 |
Why?
|
HIV Infections | 2 | 2016 | 17564 | 0.040 |
Why?
|
Mutation | 2 | 2014 | 30243 | 0.040 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 733 | 0.040 |
Why?
|
Remission Induction | 2 | 2015 | 2408 | 0.040 |
Why?
|
Family Characteristics | 1 | 2024 | 1002 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2024 | 885 | 0.040 |
Why?
|
Polypharmacy | 1 | 2021 | 307 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 239 | 0.040 |
Why?
|
Death | 1 | 2023 | 683 | 0.040 |
Why?
|
Physician Assistants | 1 | 2021 | 190 | 0.040 |
Why?
|
Chronic Disease | 2 | 2024 | 9382 | 0.040 |
Why?
|
Odds Ratio | 2 | 2021 | 9687 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 564 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 798 | 0.040 |
Why?
|
Nurse Practitioners | 1 | 2021 | 271 | 0.040 |
Why?
|
Tracheostomy | 1 | 2022 | 433 | 0.040 |
Why?
|
HIV-1 | 1 | 2015 | 6966 | 0.040 |
Why?
|
Infant, Low Birth Weight | 1 | 2022 | 875 | 0.040 |
Why?
|
Anxiety | 2 | 2023 | 4655 | 0.040 |
Why?
|
Patient Readmission | 2 | 2024 | 3308 | 0.040 |
Why?
|
Child, Preschool | 3 | 2024 | 42623 | 0.040 |
Why?
|
Anastomotic Leak | 1 | 2018 | 171 | 0.030 |
Why?
|
Tumor Burden | 1 | 2023 | 1909 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 941 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2024 | 10494 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10358 | 0.030 |
Why?
|
Axons | 1 | 2024 | 1678 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14766 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2024 | 2216 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12561 | 0.030 |
Why?
|
Caribbean Region | 1 | 2016 | 193 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1014 | 0.030 |
Why?
|
Naphthalimides | 1 | 2015 | 22 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 20 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2023 | 5808 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2022 | 861 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10125 | 0.030 |
Why?
|
Daunorubicin | 1 | 2015 | 157 | 0.030 |
Why?
|
Surgical Flaps | 1 | 2023 | 1683 | 0.030 |
Why?
|
Prosencephalon | 1 | 2016 | 306 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1556 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2020 | 1276 | 0.030 |
Why?
|
United States | 5 | 2022 | 73121 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2014 | 102 | 0.030 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 184 | 0.030 |
Why?
|
Mice | 5 | 2024 | 82045 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2925 | 0.030 |
Why?
|
Sexual Partners | 1 | 2019 | 806 | 0.030 |
Why?
|
Mexico | 1 | 2016 | 766 | 0.030 |
Why?
|
Dyspnea | 1 | 2021 | 1352 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2200 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4931 | 0.030 |
Why?
|
Intention | 1 | 2016 | 349 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2024 | 26395 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 551 | 0.030 |
Why?
|
Cytarabine | 1 | 2015 | 697 | 0.030 |
Why?
|
Mothers | 1 | 2023 | 2210 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 903 | 0.030 |
Why?
|
Microspheres | 1 | 2015 | 789 | 0.030 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 360 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 695 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1734 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 940 | 0.020 |
Why?
|
Emotions | 1 | 2023 | 2773 | 0.020 |
Why?
|
Androstadienes | 1 | 2012 | 348 | 0.020 |
Why?
|
Patient Compliance | 1 | 2021 | 2696 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2021 | 2239 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2017 | 1034 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3629 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2016 | 666 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2015 | 2228 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3771 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1339 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1568 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2015 | 2072 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2015 | 1674 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2731 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3910 | 0.020 |
Why?
|
Animals | 5 | 2024 | 169418 | 0.020 |
Why?
|
Adenine | 1 | 2015 | 993 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3471 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2024 | 14728 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3708 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2224 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 13026 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3619 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8559 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1884 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2015 | 2640 | 0.020 |
Why?
|
Databases, Factual | 1 | 2024 | 8081 | 0.020 |
Why?
|
Tamoxifen | 1 | 2012 | 968 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4342 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2022 | 7863 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15460 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17149 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2015 | 1924 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 14158 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8908 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3637 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6657 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4861 | 0.020 |
Why?
|
Pain | 1 | 2021 | 5096 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8051 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2575 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4120 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2024 | 20231 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2014 | 2450 | 0.020 |
Why?
|
Smoking | 1 | 2022 | 9099 | 0.020 |
Why?
|
Quality of Health Care | 1 | 2020 | 4340 | 0.020 |
Why?
|
Mammography | 1 | 2015 | 2436 | 0.010 |
Why?
|
Genomics | 1 | 2020 | 5909 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2014 | 2987 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7451 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 3463 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8753 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15965 | 0.010 |
Why?
|
Physicians | 1 | 2021 | 4615 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11674 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 4417 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4453 | 0.010 |
Why?
|
Models, Statistical | 1 | 2017 | 5103 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4534 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7605 | 0.010 |
Why?
|
Medicare | 1 | 2020 | 6881 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15880 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12096 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11138 | 0.010 |
Why?
|
Neurons | 1 | 2020 | 9504 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41797 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 19041 | 0.010 |
Why?
|
Depression | 1 | 2019 | 8235 | 0.010 |
Why?
|
Mental Disorders | 1 | 2019 | 6879 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5827 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2022 | 20762 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9507 | 0.010 |
Why?
|